We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Graphene-Based Transistor Detects Bacteria in Microdroplets

By LabMedica International staff writers
Posted on 01 Jul 2019
A team of Japanese researchers developed a graphene-based field-effect transistor and used it to detect the gastric cancer pathogen Helicobacter pylori in fluid microdroplets.

Graphene is an allotrope of carbon in the form of a two-dimensional hexagonal lattice in which one atom forms each vertex. More...
It is the basic structural element of other allotropes, including graphite, charcoal, carbon nanotubes, and fullerenes. At one atom thick, graphene is the thinnest material known to man and is also one of the strongest, being approximately 200 times stronger than steel. It is an excellent conductor of heat and electricity and has interesting light absorption properties.

Investigators at Osaka University (Japan) coated micro sized sheets of graphene with specific antibodies to create highly sensitive graphene-based field effect transistors (GFETs) for use as biosensors and chemical sensors. Due to the two-dimensional structure of graphene, along with its physical properties, GFETs offer increased sensitivity, and reduced instances of false positives responses in sensing applications.

To use a GFET to detect bacteria, the investigators faced a peculiar physical limitation. The measurable range from the graphene surface is highly restricted by Debye screening, with characteristic length less than one nanometer at physiological ionic strength. This screening effect prevented the graphene sheet from being affected by binding of bacteria to the antibody coating.

To overcome the Debye screening limitation, the investigators introduced a way to monitor chemical reactions generated by the bacteria in the presence of reagents added by microfluidics to a droplet of liquid. The low molecular weight chemicals produced in the reactions were able to penetrate the Debye screen and reach the graphene surface. Electrical signals built up on the graphene surface due to these reactions were used to calculate the number of bacteria in the droplet.

The investigators demonstrated that they could achieve quantitative measurements of a target based on the site-binding model and real-time measurement of enzyme kinetics in femtoliter (10 x -15 liter or a cubic microliter) microdroplets.

The combination of a G-FET and microfluidics, called by the investigators a “lab-on-a-graphene-FET”, detected the enzyme urease with high sensitivity in the zeptomole (one 10 x -21th part of a mole, or about 600 molecules) range in 100 millimolar sodium phosphate buffer. Furthermore, the lab-on-a-graphene-FET detected the gastric cancer pathogen Helicobacter pylori captured at a distance greater than the Debye screening length from the G-FET.

"Our biosensor is essentially a mini laboratory on a graphene FET. This sensor demonstrates how two-dimensional materials such as graphene are getting closer to being applied in practical medical and healthcare applications," said first author Dr. Takao Ono, an assistant professor in the institute of scientific and industrial research at Osaka University.

The use of the G-FET device to detect H. pylori was described in the June 12, 2019, issue of the journal ACS Nano Letters.

Related Links:
Osaka University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.